1. A case of etanercept (anti-TNF agent) induced granulomas on the lids
- Author
-
Say Aun Quah, Hidayat Bhutto, Sid Goel, Haider R. Cheema, and Timothy Gillott
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,business.industry ,Retrospective cohort study ,Disease ,medicine.disease ,Dermatology ,Etanercept ,Ophthalmology ,medicine.anatomical_structure ,hemic and lymphatic diseases ,Granuloma ,Rheumatoid arthritis ,medicine ,Tumor necrosis factor alpha ,Eyelid ,Adverse effect ,business ,medicine.drug - Abstract
Sarcoid-like granulomas are a rare adverse effect of TNF-α inhibitors that are becoming increasingly reported in the literature. A retrospective study in France estimated this adverse effect to occur in 0.04% patients. We report an important reversible cause that is more commonly being seen.A 70 year old lady presented with multiple lesions on her lids in the ophthalmology clinic. Histology confirmed that they were sarcoid-like granulomas. The patient had been started on etanercept (anti-TNF agent) a few months prior for rheumatoid arthritis. Investigations were undertaken to rule out differentials such as autoimmune conditions and infective causes like tuberculosis.After ruling out an active inflammatory disease and an autoimmune cause, etanercept induced granulomas were considered. Etanercept was stopped. This resulted in the resolution of granulomas over the course of a few months.Etanercept induced granulomas resolve when the anti-TNF agent is discontinued; however, some patients may require treatment with steroids.As this case demonstrates, ophthalmologists should be aware that anti-TNF agents can cause non-caseating granulomas, which can be cutaneous or pulmonary. This can help to result in more prompt diagnoses and appropriate treatment.
- Published
- 2021